Celltrion completes clinical trials for Remsima SC for European approval
Celltrion completed a Phase III clinical trial to get approval of ‘Remsima SC(CT-P13 SC),’ a subcutaneous injection version of the antibody biosimilar for the treatment of autoimmune therapy ‘Remsima(generic name: infliximab),’ announced that they were about to finish the approval process for Eur...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.